By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
Life Science Nation’s next conference, Digital RESI March, is coming up in just over a month. We are excited to continue facilitating meaningful connections between early-stage life science companies and investors/strategic partners through this 3-day virtual conference, which will include a robust agenda of investor panels, workshops (including a new educational track), and the Innovator’s Pitch Challenge (IPC), through which we will have life science companies present live pitches in front of a judging panel.
We expect 300+ investors to join the upcoming event. With a 24-hour meeting capacity, attendees will be able to join the conference at the comfort of their home and schedule meetings based on their availability, regardless of what time zone they are in.
Below is a selected list of participating investors that you can expect to meet at Digital RESI March. If you are actively fundraising and looking to get in front of more investors, make sure to register by tomorrow to save $200 on your registration!
Partial List of Digital RESI March Confirmed Investors
By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series
Digital RESI March will feature a novel entrepreneurial education track, the LSN Global Partnering Campaign and Roadshow Preparation course, which will include six classes total, two classes that will be delivered each day of the 3-day virtual event. This education focus will be for entrepreneurs who are starting to plan for their fundraising and licensing partner search and how LSN can help. An important theme of the education will concern how to plan and execute a global roadshow efficiently, which can greatly determine an early-stage entity’s success when moving from their regional environment to the global competitive landscape. The education sessions are highlighted below:
Participating in the classes will allow the attendees to hear firsthand from LSN Founder and CEO, Dennis Ford, on issues including the importance of getting your company story straight, cogently weaving this narrative through multiple modalities (tagline to pitch deck), and how to avoid some of the most common pitfalls that catch first-time CEOs off-guard. Throughout the sessions on Wednesday (3/15) and Thursday (3/16), participants will hear from members of LSN’s Business Development and Investor Research teams on how to develop a professional set of marketing collateral, what the 10 myths of fundraising are, and strategies to boost partnering success in the global arena.
Attendees of RESI will be able to access the educational content in two methods: either through 1-day and 3-day partnering registrations ($695 and $995 respectively) which include the ability to book meetings with the capital investors and licensing partners who are attending Digital RESI March, or through the Audience Access Pass ($295) which grants full access to all of the education content & panels at Digital RESI March, but with no partnering.
Life Science Nation (LSN) is now focusing our efforts towards planning our upcoming fully virtual conference, Digital RESI, March 14-16. Digital RESI March will include all of the RESI favorites – Investor panels, Innovator’s Pitch Challenge, and workshops. In addition, a NEW entrepreneurial education track, the LSN Global Partnering Campaign and Roadshow Preparation course.
The LSN team hosts virtual webinars leading up to Digital RESI March to help our community of startups prepare for meeting with investors and strategic partners alike. Check out the recordings and sign up for upcoming webinars.
February 1, 12 PM EST
Delivering a Successful Virtual Pitch
The Innovator’s Pitch Challenge (IPC) returns across the upcoming 3-day digital conference, Digital RESI, March 14-16th. Being able to successfully deliver a powerful and compelling pitch to portray why your company’s unique technology should be an investor’s top interest. This workshop gives you tips from the application process, execution of the pitch and preparing for investor-led Q&A.
February 7, 12 PM EST
Tech Hub Exposure at RESI
This webinar is designed for tech hub organizations ranging from accelerators, incubators, non-profits, universities, tech transfer offices, regional organizations, and more who set up their early-stage life science startup constituents for success with their entrepreneurship and fundraising journey. It will showcase the tools and resources that LSN makes available for Tech Hubs to help their startups who’ve raised less than $2M USD in capital expand their outreach from Regional to Global, build a target list of investors, get involved with the RESI conference series, and more.
February 15, 12 PM EST
Tagline & Elevator Pitch
Distilling your company identity into a 5-7 word tagline and then expanding upon that in a 5-7 sentence elevator pitch is one of the most fundamental business development skills that early-stage entrepreneurs must master when launching global partnering campaigns. Join us to learn how to develop a compelling tagline and convincing elevator pitch to grip the attention of your target investors and licensing partners.
March 1, 12 PM EST
Strategies for Successful Partnering
Take a deep dive into your outreach campaign. Learn more about our proven successful strategy and how to craft your messages from your initial outreach and each follow up message after that.
By Erika Wu, Business Development Manager, Global Tech Hubs, LSN
Mansfield Bio-Incubator Chief Operating Officer, Alexander Margulis has been in the Life Sciences industry for over 20 years and is passionate about creating a robust and accessible entrepreneurial community among local universities, startups, and investors. Less than 1-hour away from Boston and Cambridge, the facility provides mentorship, networking opportunities and affordable private and shared spaces for research labs. In addition, they offer several resources such as access to professional advisors and assistance with government and private funding research applications. Currently, Mansfield Bio-Incubator hosts over 20 early-stage startups ranging from therapeutics to medical devices in the life sciences areas of oncology, women’s health, animal health, biomaterials, and more.
Listen to our conversation to learn more about how Alexander and his team are creating, growing, and ensuring the success of the next generation of life science companies at Mansfield Bio-Incubator.
Contact Erika Wu, Business Development Manager, Global Tech Hubs of LSN to learn about tech hub offer.
An investment group with multiple investment vehicles manages approx. $1.5B targeted on healthcare and life science under management. The firm launched a new vehicle in 2020 to invest in digital health technologies. The group will invest $1-2M, mainly in seed-series A companies developing software-based digital technologies. While the firm will invest globally, they are looking for companies targeting the US market.
The firm is interested in software-based digital health companies. The group will not invest in wearables or smart devices. The firm invests primarily in B2B or B2B2C companies, and looks for technologies that have clear cost saving or revenue generating aspect for clients.
The firm is a very active investor, leveraging their network and broad-cross sector activity to help their portfolio companies. The group is looking for companies that, at minimum, have a viable understanding of the US healthcare market.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
A venture capital and growth equity firm providing expertise and funding to companies with global ambitions in healthcare technologies. The firm is headquartered in Western Europe with teams in the US. The firm is currently making investments from a relatively new fund closed in 2021. The firm prefers to be the lead investor and possibly co-lead, seeking to allocate US$20-30 million (in equity) per company through subsequent rounds of investment. The firm invests in growth-stage companies that are based in the US and Europe and is actively seeking new investment opportunities.
The firm invests in medical devices, digital health, and diagnostic technologies. The firm focuses on companies that can address a specific unmet medical need or deliver considerable improvements to care delivery. Innovative healthcare technologies with a therapeutic focus are of high interest. The firm is opportunistic in terms of subsectors and indications and seeks companies that are in commercial ramp-up.
The firm requests a board seat in each portfolio company and generally holds a significant minority stake. Companies seeking investment should be led by a strong and experienced management team and have the support of technical experts in the relevant technology.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
An investment firm headquartered in Western Europe, with additional offices in USA and Asia, has a fund dedicated to investing in 25-28 companies in Seed to Series A financing rounds. The firm seeks to invest in innovations directly related to the prevention of age-associated diseases, extension of a healthy lifespan, and improving the performance of humans and animals. The firm’s initial check size can range from $500K – 1.5M, and the firm is open to global opportunities.
Within life sciences, the firm is most interested in therapeutics and diagnostics companies, and will also consider digital health. Medical devices with traditional regulatory pathways are generally out of scope for the firm. Within these sectors, interest areas can include gene therapy, telomere attrition, proteostasis, regenerative medicine, personalized diagnostics/biomarkers, preventative therapies, cognitive enhancement, and more. That said, the firm has no strong interest in particular technologies and is open to all modalities. The firm is also opportunistic in terms of stage of development.
The firm seeks companies with strong, protectable IP with clear origins and ownership, backed by a diverse team with a strong track record and technologies with validated proof of concept. The firm has a 3-step due diligence process which includes: (1) initial review, (2) additional review – where the firm looks more closely into main differentiating factors of the company (IP, business model, etc.), and (3) final review. The firm is open to leading, co-leading, or co-investing, and has a strong co-investment and syndication network of likeminded investors.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
